4DMedical Ltd (ASX: 4DX) is back on the radar after an active start to the week.
The stock is currently up 2.56% to $5.99 after earlier touching an intraday high of $6.38.
That pullback has come as the broader market softened, with the S&P/ASX 200 Index (ASX: XJO) down 0.1% to 8,935 points.
Even with today’s volatility, the overall trend remains strong. The shares are up roughly 50% in 2026 and 2,000% over the past year.
Here’s what was announced.
Image source: Getty Images
Several updates hit at the same time
According to the release, 4DMedical reported a series of developments across commercial, regulatory, and its upcoming inclusion in the ASX 200.
The company confirmed a contract with GlaxoSmithKline (LSE: GSK) to support pulmonary drug development using its imaging technology.
GlaxoSmithKline is a global pharmaceutical and healthcare company headquartered in the UK. It develops vaccines, specialty medicines, and consumer health products, and is one of the largest drugmakers in the world.
The agreement runs for 1 year and will see 4DMedical provide lung imaging biomarkers across clinical trials.
4DMedical did not disclose the financial terms of the agreement.
At the same time, the company reported regulatory clearance in the UK for its CT:VQ technology.
CT:VQ is 4DMedical’s imaging technology that uses CT scans to map how air and blood move through the lungs. It produces detailed functional images that help clinicians detect and measure lung conditions without requiring invasive tests.
This follows CE Mark certification received in March and allows for immediate clinical use.
The UK is one of the largest markets for diagnostic imaging, with millions of chest scans performed each year.
The update also highlighted clearance for its coronary artery calcium analysis solution in Canada.
Reimbursement progress opens a revenue pathway
Another part of the release focused on progress in the United States.
A new reimbursement code has been established for AI-enabled coronary calcium analysis from CT scans.
The code allows hospitals to claim around US$15.50 per study in the outpatient setting.
This puts a clear revenue pathway in place without requiring additional imaging or changes to workflow. Providers can integrate the analysis into existing scans, which helps lower barriers to adoption.
Reimbursement has often been a key step in moving imaging technologies into routine clinical use.
ASX 200 entry puts the stock on more screens
4DMedical has also been added to the ASX 200 Index at market open today.
The move brings the stock into Australia’s main benchmark, which is tracked by institutional and passive funds.
Inclusion can lead to increased demand as index funds adjust their holdings.
It also increases visibility among larger investors and can improve liquidity over time.